DrugPatentWatch Database Preview

Details for Patent: 6,063,771

« Back to Dashboard

Which drugs does patent 6,063,771 protect, and when does it expire?

Patent 6,063,771 protects NATROBA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-eight countries.

Summary for Patent: 6,063,771

Title:	Formulations for controlling human lice
Abstract:	Safer pediculicidal formulations comprising a spinosyn, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier, and methods of controlling lice infestations in a human with these formulations are provided.
Inventor(s):	Snyder; Daniel Earl (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	09/338,116
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 6,063,771
Patent Claim Types: see list of patent claims	Use; Formulation; Composition;

Drugs Protected by US Patent 6,063,771

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Parapro Llc	NATROBA	spinosad	SUSPENSION;TOPICAL	022408-001	Jan 18, 2011		RX	Yes	Yes			Y			NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.

International Family Members for US Patent 6,063,771

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	326212
Australia	4700499
Australia	750046
Brazil	9911795
Canada	2337789